Ocular Therapeutix
OCUL
5.57
-0.29
-4.95%
Ocular Therapeutix
US · OCUL
#2978 by market cap
Listed 1970
5.57
-0.29
-4.95%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Announces Target Price $9.32Market Newswire · 2026/4/29
-
Rating change
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31Market Newswire · 2026/10/12
-
Rating change
William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy RatingMarket Newswire · 2026/9/26
-
Rating change
TD Cowen Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $20Market Newswire · 2026/8/4
-
RBC Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/11/10
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: Zenas BioPharma, Inc. (ZBIO), Ocular Therapeutix (OCUL)TipRanks · 2026/10/13
-
Rating change
A Quick Look at Today's Ratings for Ocular Therapeutix(OCUL.US), With a Forecast Between $18 to $31Market Newswire · 2026/6/19
-
Needham Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/11/10
-
Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q3 Revenue $12.9M, Vs. FactSet Est of $14.3MMT Newswires · 2026/11/9
-
Rating change
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/10/20
-
Rating change
UBS Initiates Ocular Therapeutix(OCUL.US) With Buy Rating, Announces Target Price $14Market Newswire · 2026/10/12
-
Rating change
Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $23Market Newswire · 2026/6/25
-
Rating change
Baird Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $30Market Newswire · 2026/6/18
-
Rating change
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21Market Newswire · 2026/4/30
-
Rating change
Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21Market Newswire · 2026/5/7
-
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $28Market Newswire · 2026/11/10
-
Rating change
A Quick Look at Today's Ratings for Ocular Therapeutix(OCUL.US), With a Forecast Between $18 to $30Market Newswire · 2026/5/6
-
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $27Market Newswire · 2026/11/10
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL)TipRanks · 2026/6/19
-
Rating change
Clear Street Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $28Market Newswire · 2026/8/18
-
Rating change
RBC Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/7/30
-
Needham Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/9/29
-
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $27Market Newswire · 2026/10/13
-
Rating change
Analysts Conflicted on These Healthcare Names: Ocular Therapeutix (OCUL) and Aardvark Therapeutics, Inc. (AARD)TipRanks · 2026/3/2
-
Rating change
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $27Market Newswire · 2026/3/3
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Ocular Therapeutix discussion 0 comments